Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia
Exploratory analysis of CERA data shows sustained and stable control of anemia
July 7th, 2005
New data from a year-long phase II study have shown that CERA (continuous erythropoietin receptor activator), an investigational antianemia agent being developed by Roche, provided sustained and stable control of hemoglobin levels with dosing intervals of up to 4 weeks in dialysis patients who suffer from anemia. These data were presented during the European Renal Association - European Dialysis and Transplant Association congress in Istanbul, Turkey. Phase II results with CERA are being confirmed in an extensive phase III clinical program. "These findings suggest that CERA may represent a convenient treatment alternative with less-frequent dosing,"...
Source: Women's Health Weekly (2005-07-07)
|
